Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Vaccines containing purified GM2 ganglioside elicit GM2 antibodies in melanoma patients.

Literature DB >> 3472242

Vaccines containing purified GM2 ganglioside elicit GM2 antibodies in melanoma patients.

P O Livingston, E J Natoli, M J Calves, E Stockert, H F Oettgen, L J Old.

Abstract

GM2, GD2, and GD3 gangliosides are expressed on the surface of human melanoma cells and represent potential targets for immunological control of melanoma growth by monoclonal antibodies and active immunization. The immunogenicity of GM2 was investigated by analyzing the humoral immune response of melanoma patients to vaccination with cell lines selected for high GM2 expression and with vaccines containing purified GM2. The whole-cell vaccine and vaccines containing purified GM2 and bacillus Calmette-Guérin (BCG) elicited GM2 antibody in a high proportion of patients, particularly in GM2/BCG-vaccinated patients pretreated with cyclophosphamide and given a GM2/BCG booster immunization. Vaccines containing purified GM2 and Salmonella minnesota R595 as the adjuvant were also effective, but only in patients pretreated with cyclophosphamide. GM2 antibodies in vaccinated patients were of the IgM class and were cytotoxic for GM2-positive targets in the presence of human complement.

Entities: Chemical Disease Gene Species

Mesh：

Substances：

Year: 1987 PMID： 3472242 PMCID： PMC304770 DOI： 10.1073/pnas.84.9.2911

Source DB: PubMed Journal: Proc Natl Acad Sci U S A ISSN： 0027-8424 Impact factor: 11.205

29 in total

1. Preparation and properties of antisera against the lipid-A component of bacterial lipopolysaccharides.

Authors: C Galanos; O Lüderitz; O Westphal
Journal: Eur J Biochem Date: 1971-12-22

2. Characterization of a human melanoma-associated ganglioside antigen defined by a monoclonal antibody, 4.2.

Authors: E Nudelman; S Hakomori; R Kannagi; S Levery; M Y Yeh; K E Hellström; I Hellström
Journal: J Biol Chem Date: 1982-11-10 Impact factor: 5.157

3. Development of a new melanoma model in C57BL/6 mice.

Authors: J Berkelhammer; R W Oxenhandler; R R Hook; J M Hennessy
Journal: Cancer Res Date: 1982-08 Impact factor: 12.701

4. Myelin gangliosides in vertebrates.

Authors: F B Cochran; R K Yu; R W Ledeen
Journal: J Neurochem Date: 1982-09 Impact factor: 5.372

5. Serological response of melanoma patients receiving melanoma cell vaccines. I. Autologous cultured melanoma cells.

Authors: P O Livingston; T Watanabe; H Shiku; A N Houghton; A Albino; T Takahashi; L A Resnick; R Michitsch; C M Pinsky; H F Oettgen; L J Old
Journal: Int J Cancer Date: 1982-10-15 Impact factor: 7.396

Review 6. Cancer immunology: the search for specificity--G. H. A. Clowes Memorial lecture.

Authors: L J Old
Journal: Cancer Res Date: 1981-02 Impact factor: 12.701

7. Anti-ganglioside antibodies in multiple sclerosis.

Authors: R Arnon; E Crisp; R Kelley; G W Ellison; L W Myers; W W Tourtellotte
Journal: J Neurol Sci Date: 1980-05 Impact factor: 3.181

8. Cell-mediated cytotoxicity for cultured autologous melanoma cells.

Authors: P O Livingston; H Shiku; M A Bean; C M Pinsky; H F Oettgen; L J Old
Journal: Int J Cancer Date: 1979-07-15 Impact factor: 7.396

9. Cell surface antigens of human malignant melanoma: definition of six antigenic systems with mouse monoclonal antibodies.

Authors: W G Dippold; K O Lloyd; L T Li; H Ikeda; H F Oettgen; L J Old
Journal: Proc Natl Acad Sci U S A Date: 1980-10 Impact factor: 11.205

10. GD3, a prominent ganglioside of human melanoma. Detection and characterisation by mouse monoclonal antibody.

Authors: C S Pukel; K O Lloyd; L R Travassos; W G Dippold; H F Oettgen; L J Old
Journal: J Exp Med Date: 1982-04-01 Impact factor: 14.307

36 in total

1. Biological agents in cancer therapy: cytokines, monoclonal antibodies and vaccines.

Authors: H F Oettgen
Journal: J Cancer Res Clin Oncol Date: 1990 Impact factor: 4.553

2. Autologous typing: a tedious but orthodox approach for defining human tumor antigens with clarity.

Authors: Hiroshi Shiku; Toshitada Takahashi
Journal: Cancer Immun Date: 2012-05-01

3. Enhanced expression of unique gangliosides with GM2-determinant in human uterine cervical carcinoma-derived cell lines.

Authors: Kyoko Tanaka; Masaki Miyazawa; Mikio Mikami; Daisuke Aoki; Kazushige Kiguchi; Masao Iwamori
Journal: Glycoconj J Date: 2016-06-06 Impact factor: 2.916

Vaccines containing purified GM2 ganglioside elicit GM2 antibodies in melanoma patients.

1. Preparation and properties of antisera against the lipid-A component of bacterial lipopolysaccharides.

2. Characterization of a human melanoma-associated ganglioside antigen defined by a monoclonal antibody, 4.2.

3. Development of a new melanoma model in C57BL/6 mice.

4. Myelin gangliosides in vertebrates.

5. Serological response of melanoma patients receiving melanoma cell vaccines. I. Autologous cultured melanoma cells.

Review 6. Cancer immunology: the search for specificity--G. H. A. Clowes Memorial lecture.

7. Anti-ganglioside antibodies in multiple sclerosis.

8. Cell-mediated cytotoxicity for cultured autologous melanoma cells.

9. Cell surface antigens of human malignant melanoma: definition of six antigenic systems with mouse monoclonal antibodies.

10. GD3, a prominent ganglioside of human melanoma. Detection and characterisation by mouse monoclonal antibody.

1. Biological agents in cancer therapy: cytokines, monoclonal antibodies and vaccines.

2. Autologous typing: a tedious but orthodox approach for defining human tumor antigens with clarity.

3. Enhanced expression of unique gangliosides with GM2-determinant in human uterine cervical carcinoma-derived cell lines.

4. A monoclonal antibody for terminal beta-galactose. Use in analysis of glycosphingolipids.

Review 5. Recent advances in the treatment of malignant melanoma with gene therapy.

Review 6. Drug delivery issues in vaccine development.

7. Metastatic melanoma secreted IL-10 down-regulates CD1 molecules on dendritic cells in metastatic tumor lesions.

8. Serological response patterns of melanoma patients immunized with a GM2 ganglioside conjugate vaccine.

9. From synthesis to biologics: preclinical data on a chemistry derived anticancer vaccine.

10. Monoclonal antibody against a lactose epitope of glycosphingolipids binds to melanoma tumour cells.